These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19498019)

  • 21. Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy.
    Mateos MV; Bringhen S; Richardson PG; Lahuerta JJ; Larocca A; Oriol A; Boccadoro M; García-Sanz R; Di Raimondo F; Esseltine DL; van de Velde H; Desai A; Londhe A; San Miguel JF; Palumbo A
    Haematologica; 2014 Jun; 99(6):1114-22. PubMed ID: 24763402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease.
    Wechalekar AD; Lachmann HJ; Offer M; Hawkins PN; Gillmore JD
    Haematologica; 2008 Feb; 93(2):295-8. PubMed ID: 18245653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis.
    Lee JY; Lim SH; Kim SJ; Lee GY; Lee JE; Choi JO; Kim JS; Kim HJ; Lee SY; Min JH; Jeon ES; Kim K
    Amyloid; 2014 Dec; 21(4):261-6. PubMed ID: 25248716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
    Davies AM; Ho C; Metzger AS; Beckett LA; Christensen S; Tanaka M; Lara PN; Lau DH; Gandara DR
    J Thorac Oncol; 2007 Dec; 2(12):1112-6. PubMed ID: 18090584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.
    Holkova B; Perkins EB; Ramakrishnan V; Tombes MB; Shrader E; Talreja N; Wellons MD; Hogan KT; Roodman GD; Coppola D; Kang L; Dawson J; Stuart RK; Peer C; Figg WD; Kolla S; Doyle A; Wright J; Sullivan DM; Roberts JD; Grant S
    Clin Cancer Res; 2011 May; 17(10):3388-97. PubMed ID: 21447728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma.
    Lee J; Suh C; Kang HJ; Ryoo BY; Huh J; Ko YH; Eom HS; Kim K; Park K; Kim WS
    Ann Oncol; 2008 Dec; 19(12):2079-83. PubMed ID: 18689866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis.
    Shimazaki C; Fuchida S; Suzuki K; Ishida T; Imai H; Sawamura M; Takamatsu H; Abe M; Miyamoto T; Hata H; Yamada M; Ando Y
    Int J Hematol; 2016 Jan; 103(1):79-85. PubMed ID: 26588925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma.
    Berenson JR; Yellin O; Patel R; Duvivier H; Nassir Y; Mapes R; Abaya CD; Swift RA
    Clin Cancer Res; 2009 Feb; 15(3):1069-75. PubMed ID: 19188182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
    Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
    Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
    William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma.
    Moore S; Atwal S; Sachchithanantham S; Streetly M; Khan I; Percy L; Narat S; D'Sa S; Rabin N; Johnston R; Schey S; Yong K
    Eur J Haematol; 2013 May; 90(5):420-5. PubMed ID: 23294279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
    J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Spigel DR; Barton J; Farley C; Schreeder M; Hon J; Greco FA
    Cancer; 2008 Aug; 113(4):765-71. PubMed ID: 18543319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach.
    Mehnert JM; Tan AR; Moss R; Poplin E; Stein MN; Sovak M; Levinson K; Lin H; Kane M; Gounder M; Lin Y; Shih WJ; White E; Rubin EH; Karantza V
    Mol Cancer Ther; 2011 Aug; 10(8):1509-19. PubMed ID: 21680752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
    Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
    Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.
    Harvey RD; Owonikoko TK; Lewis CM; Akintayo A; Chen Z; Tighiouart M; Ramalingam SS; Fanucchi MP; Nadella P; Rogatko A; Shin DM; El-Rayes B; Khuri FR; Kauh JS
    Br J Cancer; 2013 Mar; 108(4):762-5. PubMed ID: 23322195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
    San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
    Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
    Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
    Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.
    Gerecitano J; Portlock C; Moskowitz C; Hamlin P; Straus D; Zelenetz AD; Zhang Z; Dumitrescu O; Sarasohn D; Lin D; Pappanicholaou J; Cortelli BM; Neylon E; Hamelers R; Wright J; O'Connor OA
    Br J Haematol; 2009 Sep; 146(6):652-5. PubMed ID: 19624539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
    Papandreou CN; Daliani DD; Nix D; Yang H; Madden T; Wang X; Pien CS; Millikan RE; Tu SM; Pagliaro L; Kim J; Adams J; Elliott P; Esseltine D; Petrusich A; Dieringer P; Perez C; Logothetis CJ
    J Clin Oncol; 2004 Jun; 22(11):2108-21. PubMed ID: 15169797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.